Epinephrine Nasal Spray for Anaphylaxis Gets Fast Tracked by FDA

INSYS Therapeutics, Inc has announced that the (FDA) has granted Fast Track designation to the company’s epinephrine nasal spray as an investigational treatment for anaphylaxis, an acute, life-threatening allergic reaction requiring urgent treatment.

The Company say that preliminary data (n=60) of patients with seasonal allergies showed rapid absorption of intranasal epinephrine.The bioavailability of the novel epinephrine nasal spray also proved similar to that of intramuscular injection with EpiPen 0.3mg injection.

“This is an exciting milestone for people affected by severe allergies who might be seeking an alternative delivery mechanism for epinephrine,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics.

Speak Your Mind

*

INFORMATION on triggerallergy.com IS NOT MEDICAL ADVICE and any information or materials posted are intended for general informational purposes only. Any information posted on the web site is NOT a substitute for medical attention. Please see your health-care professional for medical advice and treatment.